Last reviewed · How we verify
SPH4336
At a glance
| Generic name | SPH4336 |
|---|---|
| Sponsor | Shanghai Pharmaceuticals Holding Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE2, PHASE3)
- A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. (PHASE1, PHASE2)
- Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer (PHASE2, PHASE3)
- Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. (PHASE2)
- Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas (PHASE2)
- Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPH4336 CI brief — competitive landscape report
- SPH4336 updates RSS · CI watch RSS
- Shanghai Pharmaceuticals Holding Co., Ltd portfolio CI